Sugi Predict

Sugi Predict / Compounds / SCHEMBL16554022

SCHEMBL16554022

SCHEMBL16554022

CCC(CC)COC(=O)C(C)NP(=O)(Oc1ccc([N+](=O)[O-])cc1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ BCHE P06276 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ CES2 O00748 1/20 0.44
▸ CES1 P23141 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.42
▸ MAPT P10636 5/20 0.42
▸ CYP3A4 P08684 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ BCL9 O00512 1/20 0.40
▸ CTNNB1 P35222 1/20 0.40
▸ CRHBP P24387 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16554025 1.00 CA1 (0.45) CA1CA2BCHEACHECES2
SCHEMBL28854869 0.97 ALDH1A1 (0.47) CA1CA2BCHEACHECES2
SCHEMBL14989468 0.97 ALDH1A1 (0.47) CA1CA2BCHEACHECES2
SCHEMBL28645682 0.97 ALDH1A1 (0.47) CA1CA2BCHEACHECES2
SCHEMBL17712317 0.97 ALDH1A1 (0.47) CA1CA2BCHEACHECES2
SCHEMBL17712318 0.97 ALDH1A1 (0.47) CA1CA2BCHEACHECES2
SCHEMBL14989469 0.97 ALDH1A1 (0.47) CA1CA2BCHEACHECES2
SCHEMBL26276657 0.90 CA1 (0.44) CA1CA2BCHEACHECES2
SCHEMBL18666861 0.90 CA1 (0.46) CA1CA2BCHEACHECES2
SCHEMBL17719235 0.90 CA1 (0.44) CA1CA2BCHEACHECES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-11-30 — — US disclosed
CN-110804072-B Dioxolane analogues of uridine for use in the treatment of cancer 美迪维尔公司 2023-05-12 — — CN disclosed
CN-110790789-B Dioxolane analogues of uridine for use in the treatment of cancer 美迪维尔公司 2023-05-12 — — CN disclosed
CN-115996928-A 1' -cyanonucleoside analogs and uses thereof 吉利德科学公司 2023-04-21 — — CN disclosed
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-04-20 — — US disclosed
CN-115175735-A Antiviral compounds 吉利德科学公司 2022-10-11 — — CN disclosed
US-11447511-B2 Dioxolane analogues of uridine for the treatment of cancer MEDIVIR AB (SE) 2022-09-20 — — US disclosed
EP-3572410-B1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2022-07-20 — — EP disclosed
CN-108676047-B HCV polymerase inhibitors 美迪维尔公司 2021-04-02 — — CN disclosed
US-20210054008-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2021-02-25 — — US disclosed
US-9540411-B2 HCV polymerase inhibitors MEDIVIR AB (SE) 2017-01-10 — — US disclosed
US-20160340380-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2016-11-24 — — US disclosed
US-9481703-B2 HCV polymerase inhibitors MEDIVIR AB (SE) 2016-11-01 — — US disclosed
US-20160271160-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2016-09-22 — — US disclosed
EP-3057976-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2016-08-24 — — EP disclosed
EP-3041855-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2016-07-13 — — EP disclosed
WO-2016030335-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2016-03-03 — — WO disclosed
US-20150175648-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-06-25 — — US disclosed
WO-2015056213-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-04-23 — — WO disclosed
WO-2015034420-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160271160-A1 HCV POLYMERASE INHIBITORS POLI, POLB, POLL CA1 4835/4885CA2 4562/4885BCHE 2610/4885
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NT5C CA1 4735/4885CA2 4865/4885BCHE 2068/4885
US-20150175648-A1 HCV POLYMERASE INHIBITORS POLI, POLB, POLL CA1 4835/4885CA2 4562/4885BCHE 2610/4885
US-20160340380-A1 HCV POLYMERASE INHIBITORS POLI, POLB, POLL CA1 4835/4885CA2 4562/4885BCHE 2610/4885
US-20210054008-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR CA1 4799/4885CA2 4866/4885BCHE 2135/4885
US-11447511-B2 Dioxolane analogues of uridine for the treatment of cancer ADORA3, DUT, NTPCR CA1 4799/4885CA2 4866/4885BCHE 2135/4885
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR CA1 4799/4885CA2 4866/4885BCHE 2135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback